《高盛認股證牛熊證》藥明反彈走高 北水低位吸納 留意貼價購25642、中期購18980,新上市牛55778
正股表現:藥明生物(2269)日前急挫,下試55元低位,及後穩守兼反彈,本週重上60元水平,今早繼續上升。早上高開約0.3%後升幅擴大,最高見64元,觸及一週高位。現報63.55元,升約4%。
資金流向:觀察個股輪證資金流向,認沽證於本週二錄得資金流入後,昨日獲資金轉向沽出。牛熊證方面,昨日流入牛證的資金除了較集中在58以上收回價的近牛外,47元收回區域的遠牛亦獲資金流入。昨日部署熊證的資金沽出近熊,並有部分轉倉至較遠收回價的產品。
據港股通數據顯示,昨日北水積極趁低吸納藥明生物,共有5.5億元淨買入,爲昨日最多北水買入個股。
產品選擇:投資者如看好,認購證方面的貼價選擇可留意年期約6個月的新上市藥明購25642。中期選擇可留意低面值藥明購18980。牛證方面可留意新上市藥明牛55778,遠牛選擇可留意藥明牛53247,與現價有約18及14元收回距離。
藥明購25642,行使價66.9元,2022年08月08日到期,實際槓桿2.9倍,貼價、新上市
藥明購18980,行使價90元,2022年09月28日到期,實際槓桿3.7倍,中期、低面值
藥明牛55778,收回價45元,行使價43.5元,換股比率100,槓桿比率3.1倍,新上市
藥明牛53247,收回價40元,行使價38.5元,換股比率100,槓桿比率2.5倍,相近收回價遠牛中槓桿最高
投資者如看淡,可留意屬遠熊的藥明熊61312,與現價有約36元收回距離。
藥明熊61312,收回價100元,行使價101.5元,換股比率100,槓桿比率1.6倍,近36元收回距離遠熊
注: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.